Journal: Molecular Pharmaceutics

Article Title: Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo – In Vitro – In Silico Approach

doi: 10.1021/acs.molpharmaceut.3c00016

Figure Lengend Snippet: PBPK plasma predictions. Observed and simulated encorafenib exposures as a function of time following administration of a single 100 mg dose of encorafenib in fasted, fed, and fasted with coadministration conditions. Simulations are depicted by the solid lines, whereas the mean encorafenib concentration observed at each time point are depicted as dots. n = number of participants used to calculate the mean encorafenib concentration at each time point.

Article Snippet: Simulations were performed using the commercially available PBPK modeling platform GastroPlus 9.8 (Simulations Plus, Inc., Lancaster, CA).

Techniques: Clinical Proteomics, Concentration Assay

Journal: Molecular Pharmaceutics

Article Title: Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo – In Vitro – In Silico Approach

doi: 10.1021/acs.molpharmaceut.3c00016

Figure Lengend Snippet: PBPK Model Parameters

Article Snippet: Simulations were performed using the commercially available PBPK modeling platform GastroPlus 9.8 (Simulations Plus, Inc., Lancaster, CA).

Techniques: Diffusion-based Assay, Solubility, In Vitro, Permeability, In Vivo

Journal: Molecules

Article Title: Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography–Mass Spectrometric Method

doi: 10.3390/molecules25092209

Figure Lengend Snippet: The simulated two-compartment model of SCH 58261 after IV administration using GastroPlus ™ , the predicted and observed time concentration profiles.

Article Snippet: The compartment model of GastroPlus TM (version 9.5; Simulations Plus, Inc., Lancaster, CA, USA) was used for parameter sensitivity analysis.

Techniques: Concentration Assay